CYTK insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 91% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 10 officers and directors who sold. 15 are left out

Left out: Robert Blum, Fady Malik, John Henderson, Sung Lee, Andrew Callos, Wendall Wierenga, Nancy Wysenski, Lynne Parshall, Muna Bhanji, Robert Harrington, Edward Kaye, Robert Landry, James Daly, Wendell Wierenga and Jeffrey Hessekiel (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Robert Blum

President & CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$17.3M84% planned, 16% to cover taxes

Andrew Callos

EVP, Chief Commercial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$16.0M96% planned, 4% to cover taxes

Sung Lee

EVP, Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.7M95% planned, 5% to cover taxes

Fady Malik

EVP Research & Development

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.7M81% planned, 19% to cover taxes

Edward Kaye

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.4MDisclosed plan

All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 6, 2026Fady Malik sold 3.5K shares ($215K) under a disclosed trading plan. 3.5K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Fady Malik EVP Research & Development	3,500	$61.38	n/a	n/a	Oct 6, 2026	Oct 6, 2026

Sep 28, 2026Robert Blum sold 7.5K shares ($491K) under a disclosed trading plan. 7.5K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Robert Blum President & CEO, Director	7,500	$65.46	n/a	n/a	Sep 28, 2026	Sep 28, 2026

Sep 22, 2026Fady Malik sold 3.5K shares ($239K) under a disclosed trading plan. 3.5K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Fady Malik EVP Research & Development	3,500	$68.29	n/a	n/a	Sep 22, 2026	Sep 22, 2026

Sep 15, 20262 insiders sold 99K shares ($6.9M) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Robert Blum President & CEO, Director	97,926	$69.33	n/a	n/a	Sep 15, 2026	Sep 15, 2026
Robert Landry Director	1,000	$72.13	n/a	n/a	Sep 15, 2026	Sep 15, 2026

Sep 14, 2026Robert Blum sold 7.5K shares ($551K) under a disclosed trading plan. 7.5K shares came in from vesting or option exercises the same day, so the holding fell by 1.4K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Robert Blum President & CEO, Director	7,500	$73.44	n/a	n/a	Sep 14, 2026	Sep 15, 2026

Show all 6 events

Sep 14, 2026Robert Blum gave away 1.4K shares as a gift. 7.5K shares came in from vesting or option exercises the same day, so the holding fell by 1.4K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Robert Blum President & CEO, Director	1,350	n/a	n/a	n/a	Sep 14, 2026	Sep 15, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Cytokinetics Inc CEO selling stock?

Yes. Robert Blum sold 250K shares ($17.3M) in the past 12 months, 84% of it under a trading plan disclosed in the filings.

Why are Cytokinetics Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 91% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 9% were to cover taxes. A trading plan schedules sales in advance.

Are any Cytokinetics Inc insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Robert Blum President & CEO, Director	$17.3M 250K shares	Not confirmed share of stake is being verified. Why	84% under a disclosed plan, 16% to cover taxes
Andrew Callos EVP, Chief Commercial Officer	$16.0M 237K shares	Not confirmed share of stake is being verified. Why	96% under a disclosed plan, 4% to cover taxes
Sung Lee EVP, Chief Financial Officer	$5.7M 72K shares	Not confirmed share of stake is being verified. Why	95% under a disclosed plan, 5% to cover taxes
Fady Malik EVP Research & Development	$4.7M 69K shares	Not confirmed share of stake is being verified. Why	81% under a disclosed plan, 19% to cover taxes
Edward Kaye Director	$2.4M 36K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
John Henderson Director	$2.1M 29K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Wendell Wierenga Director	$1.9M 28K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Lynne Parshall Director	$1.4M 20K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Robert Landry Director	$147K 2K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Robert Harrington Director	$144K 2.1K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 15 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Robert Blum

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Robert Blum are complete.

President & CEO, Director

n/a

−250K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Blum

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Blum are complete; balances and unit counts will be added when the check is finished.

−3.4Kgifted (net of own trusts)

−39Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
149,245	$10.60	Feb 28, 2027	$7.6M
1,568	$63.75	Mar 14, 2034	$0
69,464	$63.75	Mar 14, 2034	$0
2,254	$44.36	Mar 13, 2035	$38K
176,547	$44.36	Mar 13, 2035	$3.0M
1,665	$60.06	Mar 14, 2036	$2K
111,864	$60.06	Mar 14, 2036	$148K

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Fady Malik

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Fady Malik are complete.

EVP Research & Development

n/a

−69K

n/a

Vesting, gifts, unvested awards and holding lines for Fady Malik

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Fady Malik are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−3.1Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
19,886	$7.80	Feb 27, 2028	$1.1M
1,541	$63.75	Mar 13, 2034	$0
23,103	$63.75	Mar 14, 2034	$0
2,293	$44.36	Mar 13, 2035	$39K
58,465	$44.36	Mar 13, 2035	$995K
1,665	$60.06	Mar 14, 2036	$2K
39,527	$60.06	Mar 14, 2036	$52K

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

John Henderson

Director

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for John Henderson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Henderson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Sung Lee

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sung Lee are complete.

EVP, Chief Financial Officer

n/a

−72K

n/a

Vesting, gifts, unvested awards and holding lines for Sung Lee

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sung Lee are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−2.4Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,709	$48.51	May 30, 2034	$344K
6,011	$44.36	Mar 13, 2035	$102K
31,197	$44.36	Mar 13, 2035	$531K
1,665	$60.06	Mar 14, 2036	$2K
29,480	$60.06	Mar 14, 2036	$39K
52,304	$48.51	May 30, 2034	$673K
8,640	$44.36	Mar 13, 2035	$147K
39,681	$44.36	Mar 13, 2035	$675K

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Andrew Callos

EVP, Chief Commercial Officer

n/a

−237K

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Callos

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Callos are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−2Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,070	$39.13	Mar 6, 2033	$291K
18,346	$63.75	Mar 14, 2034	$0
1,224	$63.75	Mar 14, 2034	$0
2,749	$44.36	Mar 14, 2035	$47K
47,593	$44.36	Mar 13, 2035	$810K
1,665	$60.06	Mar 14, 2036	$2K
29,480	$60.06	Mar 14, 2036	$39K

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Wendall Wierenga

Director

n/a

Vesting, gifts, unvested awards and holding lines for Wendall Wierenga

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Wendall Wierenga are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Nancy Wysenski

Director

n/a

Vesting, gifts, unvested awards and holding lines for Nancy Wysenski

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nancy Wysenski are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Lynne Parshall

Director

n/a

−20K

n/a

Vesting, gifts, unvested awards and holding lines for Lynne Parshall

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lynne Parshall are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Muna Bhanji

Director

n/a

Vesting, gifts, unvested awards and holding lines for Muna Bhanji

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Muna Bhanji are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Robert Harrington

Director

n/a

−2.1K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Harrington

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Harrington are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Edward Kaye

Director

n/a

−36K

n/a

Vesting, gifts, unvested awards and holding lines for Edward Kaye

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Edward Kaye are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,636	$60.50	May 15, 2034	$3K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Robert Landry

Director

n/a

−2K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Landry

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Landry are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,538	$42.21	Feb 12, 2035	$490K
10,880	$30.00	May 13, 2035	$341K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

James Daly

Director

n/a

Vesting, gifts, unvested awards and holding lines for James Daly

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Daly are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,450	$37.84	Aug 19, 2035	$646K
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Wendell Wierenga

Director

n/a

−28K

n/a

Vesting, gifts, unvested awards and holding lines for Wendell Wierenga

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Wendell Wierenga are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,301	$77.15	May 26, 2036	$0

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Jeffrey Hessekiel

Chief Legal & Admin Officer

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Hessekiel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Hessekiel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,325	$60.06	Mar 14, 2036	$11K
22,820	$60.06	Mar 14, 2036	$30K

Estimate: options held × ($61.38 − strike price), using the most recent insider trade price on Form 4 (Oct 6, 2026), not a market close.

Holdings and share of stake for Cytokinetics Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$51.8M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $51.8M across 745,142 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $47.1M · 91%

The lighter segment is sales with no plan disclosed in the filing ($4.7M), including tax-related sales outside a plan.

Taxes

$4.7M of sales (9.0%) cite tax obligations in their footnotes. Separately, 46,773 shares ($3.1M) were withheld by the company for taxes, which isn't a market sale. Example: Andrew Callos, Mar 17, 2026

Charitable gifts · 1.4K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Robert Blum President & CEO, Director	250K	$17.3M	84%	33%	Oct 16, 2025 to Sep 28, 2026
Andrew Callos EVP, Chief Commercial Officer	237K	$16.0M	96%	31%	Dec 5, 2025 to Aug 31, 2026
Sung Lee EVP, Chief Financial Officer	72K	$5.7M	95%	11%	Mar 17, 2026 to Jul 1, 2026
Fady Malik EVP Research & Development	69K	$4.7M	81%	9%	Oct 21, 2025 to Oct 6, 2026
Edward Kaye Director	36K	$2.4M	100%	5%	Nov 11, 2025 to Jun 1, 2026
John Henderson Director	29K	$2.1M	100%	4%	Dec 2, 2025 to May 5, 2026
Wendell Wierenga Director	28K	$1.9M	100%	4%	Oct 27, 2025 to May 5, 2026
Lynne Parshall Director	20K	$1.4M	100%	3%	Nov 19, 2025 to Sep 1, 2026
Robert Landry Director	2K	$147K	100%	0.3%	Sep 11, 2026 to Sep 15, 2026
Robert Harrington Director	2.1K	$144K	100%	0.3%	Dec 1, 2025 to Dec 1, 2025

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$994K	$994K	$0	$0
Nov 2025	$943K	$943K	$0	$0
Dec 2025	$7.8M	$7.8M	$0	$0
Jan 2026	$1.0M	$1.0M	$0	$0
Feb 2026	$984K	$984K	$0	$0
Mar 2026	$7.1M	$2.4M	$4.7M	$0
Apr 2026	$3.4M	$3.4M	$0	$0
May 2026	$7.3M	$7.3M	$0	$0
Jun 2026	$6.2M	$6.2M	$0	$0
Jul 2026	$4.9M	$4.9M	$0	$0
Aug 2026	$2.1M	$2.1M	$0	$0
Sep 2026	$8.8M	$8.8M	$0	$0
Oct 2026	$215K	$215K	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 1.6x the 5-year average. 10 insiders sold; the average is 8 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	745K	10	$51.8M
Oct 13, 2025 1 year earlier	397K	8	$17.4M
Oct 13, 2024 2 years earlier	511K	8	$30.8M
Oct 14, 2023 3 years earlier	351K	7	$13.4M
Oct 14, 2022 4 years earlier	808K	12	$34.0M
Oct 14, 2021 5 years earlier	304K	6	$7.4M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty15 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Cytokinetics Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,385 filings on record, 127 filed in the 12-month period, and how we read them

All 1,385 Forms 3, 4 and 5 on record for Cytokinetics Inc (SEC CIK 1061983), filed from Apr 28, 2004 to Oct 6, 2026; 127 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Probable 1-for-6 stock split on or before Jun 24, 2013 (split date stated in a footnote). Splits aren't reported as transactions; 5 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (46)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Robert Wong	Dec 5, 2024	18,655 shares, last reported balance as of Dec 3, 2024
Brett Pletcher	Sep 3, 2024	33,140 shares, last reported balance as of Aug 30, 2024
Santo Costa	May 16, 2024	20,600 shares, last reported balance as of May 15, 2024
Sandford Smith	Jan 3, 2024	18,801 shares, last reported balance as of Jan 2, 2024
Ching Jaw	Mar 7, 2023	87,346 shares, last reported balance as of Mar 6, 2023
Mark Schlossberg	Mar 15, 2022	103,408 shares, last reported balance as of Mar 15, 2022
David Cragg	Mar 8, 2022	153,233 shares, last reported balance as of Mar 7, 2022
Robert Califf	Jan 4, 2022	6,003 shares, last reported balance as of Jan 3, 2022
Patrick Gage	Nov 8, 2021	30,782 shares, last reported balance as of Nov 8, 2021
BVF PARTNERS L P/IL	Dec 11, 2020	463,244 shares, last reported balance as of Dec 9, 2020
Caryn McDowell	Mar 1, 2018	32,548 shares, last reported balance as of Feb 28, 2018
Peter Roddy	Mar 1, 2018	21,520 shares, last reported balance as of Feb 27, 2018
Bradley Morgan	Sep 1, 2017	46,441 shares, last reported balance as of Aug 31, 2017
Sharon Barbari	Mar 2, 2017	40,323 shares, last reported balance as of Feb 28, 2017
Andrew Wolff	Mar 2, 2017	47,255 shares, last reported balance as of Feb 28, 2017
Bonnie Charpentier	Mar 2, 2017	29,004 shares, last reported balance as of Feb 28, 2017
Elisabeth Schnieders	Mar 2, 2017	43,919 shares, last reported balance as of Feb 28, 2017
Denise Gilbert	Jan 22, 2016	No balance on record
Eastern Capital LTD	Feb 27, 2014	2,883,845 shares, last reported balance as of Feb 25, 2014
Stephen Dow	Jan 4, 2013	554,834 shares, last reported balance as of Nov 14, 2012
Stephen Dow	Jan 4, 2013	236,842 shares, last reported balance as of Nov 14, 2012
James Spudich	May 19, 2011	30,100 shares, last reported balance as of May 18, 2011
David Morgans Jr.	Mar 1, 2011	7,000 shares, last reported balance as of Feb 28, 2011
Grant Heidrich III	Jan 5, 2011	20,466 shares, last reported balance as of Nov 29, 2004
Grant Heidrich III	Jan 5, 2011	296,893 shares, last reported balance as of Nov 29, 2004
James Sabry	Jun 4, 2010	8,258 shares, last reported balance as of Aug 20, 2009
Michael Schmertzler	Jun 4, 2010	2,338,844 shares, last reported balance as of Apr 29, 2004
Michael Schmertzler	Jun 4, 2010	1,621,689 shares, last reported balance as of Jun 3, 2010
Michael Rabson	Dec 21, 2009	3,341 shares, last reported balance as of Dec 18, 2009
Mark McDade	May 22, 2009	No balance on record
Charles Homcy	May 27, 2008	No balance on record
Jay Trautman	Mar 4, 2008	8,135 shares, last reported balance as of Feb 29, 2008
SRB ASSOCIATES VI LP	Oct 29, 2004	290,492 shares, last reported balance as of Apr 29, 2004
SEVIN ROSEN FUND VI LP	Oct 29, 2004	269,286 shares, last reported balance as of Apr 29, 2004
Gail Sheridan	Jul 27, 2004	No balance on record
William Rutter	Jul 27, 2004	28,736 shares, last reported balance as of Apr 29, 2004
Suisse Credit	May 5, 2004	517,544 shares, last reported balance as of May 4, 2004
Ix Mayfield	May 4, 2004	355,286 shares, last reported balance as of May 4, 2004
SEVIN ROSEN VI AFFILIATES FUND LP	Apr 29, 2004	21,206 shares, last reported balance as of Apr 29, 2004
SRB ASSOCIATES VII LP	Apr 29, 2004	108,333 shares, last reported balance as of Apr 29, 2004
SEVIN ROSEN FUND VII LP	Apr 29, 2004	104,325 shares, last reported balance as of Apr 29, 2004
SEVIN ROSEN VII AFFILIATES FUND LP	Apr 29, 2004	4,008 shares, last reported balance as of Apr 29, 2004
SRB ASSOCIATES VIII LP	Apr 29, 2004	128,509 shares, last reported balance as of Apr 29, 2004
SEVIN ROSEN FUND VIII LP	Apr 29, 2004	125,939 shares, last reported balance as of Apr 29, 2004
SEVIN ROSEN VIII AFFILIATES FUND LP	Apr 29, 2004	2,570 shares, last reported balance as of Apr 29, 2004
John Jaggers	Apr 29, 2004	527,334 shares, last reported balance as of Apr 29, 2004

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Cytokinetics Inc insiders sold $51.8M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Cytokinetics Inc CEO selling stock?

Why are Cytokinetics Inc insiders selling?

Are any Cytokinetics Inc insiders buying?

The evidence

Taxes

Charitable gifts · 1.4K shares

Sales by month